Anti-Coagulants - Vietnam
VietnamHighlights
Market definition
In-Scope/Out-of-scope
Market structure
Reports
Methodology
- In Vietnam, the revenue in the Anti-Coagulants market is estimated to reach US$68.72m in 2025.
- It is expected to exhibit a compound annual growth rate (CAGR 2025-2029) of 8.09%, leading to a market volume of US$93.80m by 2029.
- When compared globally, United States is projected to generate the highest revenue of US$17.68bn in 2025.
- In Vietnam, the demand for anti-coagulants is steadily increasing due to an aging population and a rise in cardiovascular diseases.
- Key regions:
- Australia,
- Japan,
- United States,
- Germany,
- Europe
Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson
In-Scope
- Blood clotting inhibitors
Out-Of-Scope
- Anti-fibrinolytics
- Anti-hypertensives
- Other hematology drugs
- Other anti-thrombotic agents, such as platelet aggregation inhibitors
- Thrombolytic drugs
